RS65599B1 - Enantiomerno prečišćeni gper agonist za upotrebu u lečenju bolesnog stanja i kondicije - Google Patents
Enantiomerno prečišćeni gper agonist za upotrebu u lečenju bolesnog stanja i kondicijeInfo
- Publication number
- RS65599B1 RS65599B1 RS20240634A RSP20240634A RS65599B1 RS 65599 B1 RS65599 B1 RS 65599B1 RS 20240634 A RS20240634 A RS 20240634A RS P20240634 A RSP20240634 A RS P20240634A RS 65599 B1 RS65599 B1 RS 65599B1
- Authority
- RS
- Serbia
- Prior art keywords
- derivative
- cancer
- srr
- compound
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701726P | 2018-07-21 | 2018-07-21 | |
| EP19842049.9A EP3823617B1 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
| PCT/US2019/042827 WO2020023391A1 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65599B1 true RS65599B1 (sr) | 2024-06-28 |
Family
ID=69160978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240634A RS65599B1 (sr) | 2018-07-21 | 2019-07-22 | Enantiomerno prečišćeni gper agonist za upotrebu u lečenju bolesnog stanja i kondicije |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US20200024262A1 (https=) |
| EP (2) | EP3823617B1 (https=) |
| JP (2) | JP2021532148A (https=) |
| KR (1) | KR20210049778A (https=) |
| CN (1) | CN112469409B (https=) |
| AU (1) | AU2019310029B2 (https=) |
| BR (1) | BR112021001031A2 (https=) |
| CA (1) | CA3107109A1 (https=) |
| DK (1) | DK3823617T3 (https=) |
| ES (1) | ES2980434T3 (https=) |
| FI (1) | FI3823617T3 (https=) |
| HR (1) | HRP20240661T1 (https=) |
| HU (1) | HUE067185T2 (https=) |
| IL (2) | IL312938A (https=) |
| LT (1) | LT3823617T (https=) |
| MX (2) | MX2021000809A (https=) |
| NZ (1) | NZ771952A (https=) |
| PL (1) | PL3823617T3 (https=) |
| PT (1) | PT3823617T (https=) |
| RS (1) | RS65599B1 (https=) |
| SI (1) | SI3823617T1 (https=) |
| SM (1) | SMT202400205T1 (https=) |
| WO (1) | WO2020023391A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022091029A1 (en) * | 2020-10-30 | 2022-05-05 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| US20240376547A1 (en) * | 2021-04-08 | 2024-11-14 | Linnaeus Therapeutics, Inc. | Oncologic variations associated with cancer and methods of treatment |
| WO2022245899A2 (en) * | 2021-05-19 | 2022-11-24 | Linaeus Therapeutics, Inc. | Diagnostic methods and compositions for treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US251870A (en) * | 1882-01-03 | Automatic gate | ||
| US6809104B2 (en) * | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
| US7875721B2 (en) * | 2005-08-04 | 2011-01-25 | Stc.Unm | Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof |
| WO2008153945A2 (en) * | 2007-06-06 | 2008-12-18 | University Of South Florida | Nutraceutical co-crystal compositions |
| MX382354B (es) * | 2010-11-01 | 2025-03-13 | Celgene Car Llc | Compuestos heterocíclicos y usos de los mismos. |
| US10251870B2 (en) * | 2015-03-06 | 2019-04-09 | Stc.Unm | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity |
| AU2016246688B2 (en) * | 2015-04-06 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for decreasing, or preventing or reversing gain of, skin pigmentation in a mammalian subject |
| US11369618B2 (en) | 2016-06-17 | 2022-06-28 | The Trustees Of The University Of Pennsylvania | Compounds, compositions and methods for prevention and/or treatment of cancer |
-
2019
- 2019-07-22 ES ES19842049T patent/ES2980434T3/es active Active
- 2019-07-22 BR BR112021001031-9A patent/BR112021001031A2/pt unknown
- 2019-07-22 US US16/518,516 patent/US20200024262A1/en not_active Abandoned
- 2019-07-22 IL IL312938A patent/IL312938A/en unknown
- 2019-07-22 PT PT198420499T patent/PT3823617T/pt unknown
- 2019-07-22 HU HUE19842049A patent/HUE067185T2/hu unknown
- 2019-07-22 JP JP2021504360A patent/JP2021532148A/ja active Pending
- 2019-07-22 PL PL19842049.9T patent/PL3823617T3/pl unknown
- 2019-07-22 SM SM20240205T patent/SMT202400205T1/it unknown
- 2019-07-22 AU AU2019310029A patent/AU2019310029B2/en active Active
- 2019-07-22 CA CA3107109A patent/CA3107109A1/en active Pending
- 2019-07-22 EP EP19842049.9A patent/EP3823617B1/en active Active
- 2019-07-22 FI FIEP19842049.9T patent/FI3823617T3/fi active
- 2019-07-22 RS RS20240634A patent/RS65599B1/sr unknown
- 2019-07-22 NZ NZ771952A patent/NZ771952A/en unknown
- 2019-07-22 WO PCT/US2019/042827 patent/WO2020023391A1/en not_active Ceased
- 2019-07-22 CN CN201980048925.4A patent/CN112469409B/zh active Active
- 2019-07-22 LT LTEPPCT/US2019/042827T patent/LT3823617T/lt unknown
- 2019-07-22 EP EP24161261.3A patent/EP4356913A3/en not_active Withdrawn
- 2019-07-22 KR KR1020217002117A patent/KR20210049778A/ko not_active Ceased
- 2019-07-22 DK DK19842049.9T patent/DK3823617T3/da active
- 2019-07-22 SI SI201930756T patent/SI3823617T1/sl unknown
- 2019-07-22 HR HRP20240661TT patent/HRP20240661T1/hr unknown
- 2019-07-22 IL IL280283A patent/IL280283B2/en unknown
- 2019-07-22 MX MX2021000809A patent/MX2021000809A/es unknown
- 2019-11-13 US US16/682,821 patent/US10934277B2/en active Active
-
2021
- 2021-01-20 MX MX2024008188A patent/MX2024008188A/es unknown
- 2021-02-25 US US17/184,870 patent/US11760749B2/en active Active
- 2021-05-24 US US17/328,590 patent/US20220089576A1/en not_active Abandoned
-
2023
- 2023-08-03 US US18/364,690 patent/US20230382896A1/en not_active Abandoned
-
2024
- 2024-05-29 JP JP2024087006A patent/JP2024119868A/ja active Pending
- 2024-06-24 US US18/752,146 patent/US20250171421A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118574836A (zh) | 用于治疗癌症的环状2-胺基-3-氰基噻吩及衍生物 | |
| US20230382896A1 (en) | Enantiomerically purified gper agonist for use in treating disease states and conditions | |
| CN104606194A (zh) | Pde4的双环杂芳基抑制剂 | |
| SA97180449A (ar) | لاكتامات وإيميدات حلقية مغايرة أر الكيل وأر الكيليدين . | |
| JP2023051962A (ja) | ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用 | |
| CN106573937A (zh) | 作为fshr调节剂的吡唑化合物及其用途 | |
| CA3194868A1 (en) | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof | |
| CN116261454A (zh) | 转录激活蛋白的咪唑并哌嗪抑制剂 | |
| EP4587429B1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compounds | |
| CN116348112A (zh) | 转录激活蛋白的咪唑并哌嗪抑制剂 | |
| CN117003737A (zh) | 取代的咪唑苯基甲酮类化合物及其衍生物和药物组合物 | |
| KR20080070822A (ko) | 유도가능 산화질소 신타제 이량체화 억제제의 염 | |
| JP2020508969A (ja) | オーロラａキナーゼ選択的阻害剤 | |
| CN116969926A (zh) | 三嗪酮类化合物及其衍生物和药物组合物 | |
| CN101528228A (zh) | Pde4的双环杂芳基抑制剂 | |
| HK1225651A1 (zh) | 异吲哚啉组合物和治疗神经变性疾病的方法 |